Last updated: February 24, 2026
What is the drug associated with NDC 55111-0118?
NDC 55111-0118 refers to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy used to treat spinal muscular atrophy (SMA) in pediatric patients.
Market Landscape
Market Size and Patient Population
- SMA is a rare genetic disorder affecting approximately 1 in 10,000 live births.
- Estimated US pediatric SMA Type 1 population is around 300-400 patients annually.
- The global SMA market was valued at approximately USD 0.8 billion in 2022 and is expected to grow at a CAGR of 10% through 2030.
Key Competitors
- Biogen (Spinraza, nusinersen): Market leader with USD 950 million in 2022 revenue.
- Sarepta Therapeutics (EV Insulin, rapid-acting): Developing SMA therapies; entry expected in the next 3-5 years.
- Gene therapy entrants: Limited competitors due to high R&D barriers and regulatory requirements.
Regulatory Status
- Approved by the FDA in May 2019 for pediatric SMA patients under 2 years old.
- Approved in the EU in 2020.
- Post-approval, the therapy has seen rapid adoption in clinics with reimbursement established through CMS and private insurers.
Price and Reimbursement Landscape
Current Pricing
- List Price: US$2.1 million per treatment dose.
- Price variation exists based on negotiations, manufacturer discounts, and patient-specific factors.
Reimbursement Policies
- CMS covers Zolgensma under certain conditions, with reimbursement aligned to the list price minus discounts.
- Commercial insurers often negotiate discounts, reducing effective costs.
- Coverage limitations include age restrictions and diagnostic confirmation.
Cost Effectiveness
- Cost per quality-adjusted life year (QALY) for Zolgensma ranged between USD 150,000 and USD 200,000, depending on assumptions.
- Faster market uptake and improved insurance coverage support sustained high prices.
Market and Price Projections (2023–2030)
| Year |
Estimated Global Sales |
Key Factors |
Price Trend |
| 2023 |
USD 1.2 billion |
Growing diagnosed patient base, increased adoption |
Stable, with minor discounts applied |
| 2024 |
USD 1.3 billion |
Expanded indications, increased reimbursement |
Slight decline (~5%) due to discounts |
| 2025 |
USD 1.4 billion |
Entry into new markets, more competitive pricing |
Slight decline (~5%) |
| 2026 |
USD 1.7 billion |
Expansion into older patient groups, new formulations |
Stabilization, potential slight decrease |
| 2027 |
USD 2.0 billion |
Broader global access, patents nearing expiration |
Slight price decline (~5%) |
| 2028–2030 |
USD 2.2–2.5 billion |
Market saturation, biosimilars or generics entry after patent expiry |
Price decline accelerates (~10%) post-2030 |
Key assumptions include continued regulatory acceptance, evolving reimbursement strategies, and competitive pressures.
Patent and Regulatory Outlook
- Patent expiry expected around 2030, with exclusivity likely to diminish after that.
- Manufacturing scale-up and biosimilar development could lower prices.
Strategic Considerations
- Manufacturers should plan for gradual price reductions post-2030.
- Expansion into adult SMA indications and other neuromuscular diseases offers additional growth avenues.
- Pricing negotiations with payors will remain critical for market access.
Key Takeaways
- NDC 55111-0118 (Zolgensma) commands a high price due to its innovative gene therapy approach and limited patient population.
- The global market size is projected to reach USD 2.5 billion by 2030, with stable or slightly declining prices due to discounts, competition, and patent expiration.
- Expansion into new indications and markets will influence future sales volume more than price adjustments.
- Reimbursement policies and cost-effectiveness considerations are central to market penetration.
- Patent lifecycle management and biosimilar development are critical to future pricing strategies.
FAQs
1. When will the patent for Zolgensma expire?
Patent protection is expected to end around 2030, after which biosimilar competition may drive prices down.
2. What factors impact the pricing of gene therapies like Zolgensma?
Regulatory status, manufacturing costs, patient population size, reimbursement policies, and competitor pricing influence therapy prices.
3. How does Zolgensma compare to Spinraza in price?
Zolgensma has a higher upfront cost (USD 2.1 million) but may be more cost-effective over time compared to multiple doses of Spinraza, which is priced around USD 750,000 annually.
4. Are there any off-label uses impacting the market?
Off-label use is limited; main indications focus on pediatric SMA patients.
5. What is the potential for biosimilar development post-patent expiry?
Biosimilars are likely, which could reduce prices by 30-50% depending on market dynamics.
References
- National Organization for Rare Disorders. (2023). Spinal Muscular Atrophy (SMA). Retrieved from https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/
- IQVIA. (2022). Global Rare Disease Market Report.
- FDA. (2019). Approval of Zolgensma for SMA. Retrieved from https://www.fda.gov
- Evaluate Pharma. (2023). Gene Therapy Market Forecast.
- Centers for Medicare & Medicaid Services. (2022). Coverage of Gene Therapies.
